SCHEMBL24498481

SCHEMBL24498481

CC(C)Oc1ccc(N)c(N(C)S(C)(=O)=O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 4/20 0.49
PARP10 Q53GL7 1/20 0.39
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 2/20 0.37
GLA P06280 1/20 0.36
POLB P06746 2/20 0.36
CA2 P00918 1/20 0.36
BRD4 O60885 1/20 0.36
BRPF1 P55201 1/20 0.36
FFAR4 Q5NUL3 1/20 0.35
ALDH1A3 P47895 1/20 0.34
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
MCL1 Q07820 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
MMP3 P08254 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24497505 0.83 CYP19A1 (0.47) CYP19A1PARP10ALDH1A1KMT2APOLB
SCHEMBL23933005 0.83 ALDH1A1 (0.44) CYP19A1ALDH1A1KMT2APOLBCA2
SCHEMBL29686091 0.83 ALDH1A1 (0.44) CYP19A1ALDH1A1KMT2APOLBCA2
SCHEMBL24497565 0.82 CYP19A1 (0.46) CYP19A1PARP10ALDH1A1KMT2AGLA
SCHEMBL26514887 0.82 CYP19A1 (0.46) CYP19A1PARP10ALDH1A1KMT2AGLA
SCHEMBL24498530 0.79 CYP19A1 (0.44) CYP19A1PARP10ALDH1A1KMT2APOLB
SCHEMBL30936865 0.79 CYP19A1 (0.37) CYP19A1ALDH1A1KMT2ALMNA
SCHEMBL30936872 0.79 CYP19A1 (0.37) CYP19A1ALDH1A1KMT2ALMNA
SCHEMBL29686620 0.79 KMT2A (0.47) CYP19A1ALDH1A1KMT2APOLBCA2
SCHEMBL24498465 0.79 KMT2A (0.47) CYP19A1ALDH1A1KMT2APOLBCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101548-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD (CN) 2024-03-28 US disclosed
EP-4257587-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2023-10-11 EP disclosed
CN-116283954-A Hydroxamate compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2023-06-23 CN disclosed
CN-114901656-B Hydroximic acid ester compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2023-04-07 CN disclosed
CN-114901656-A Hydroximic acid ester compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2022-08-12 CN disclosed
WO-2022117016-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 深圳微芯生物科技股份有限公司 2022-06-09 WO disclosed
WO-2022117016-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 深圳微芯生物科技股份有限公司 2022-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101548-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF TYK2, WEE2, WEE1 CYP19A1 1198/4885PARP10 851/4885ALDH1A1 3779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.